

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: MYDECINE INNOVATIONS GROUP INC. (the "Issuer" or "Mydecine").

Trading Symbol: MYCO

Number of Outstanding Listed Securities: 166,720,845

Date: November 5, 2020

Report on Business

1. *Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month.*

During the month of October 2020, the Issuer's business and operations consisted of the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi.

2. *Provide a general overview and discussion of the activities of management.*

During the month of October 2020, the Issuer principal activities consisted of general management and administrative matters.

On October 14, 2020, the Issuer's management completed and filed the Issuer's financial statements, MD&A and officer certifications for the period ended June 30, 2020.

3. *Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.*

There were no new products or services developed or offered during the month of October 2020.

4. *Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.*

There were no products or services discontinued during the month of October 2020.

5. *Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.*

On October 14, 2020, the Issuer's wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm") engaged FreeMind Group LLC to assist NeuroPharm in securing non-

dilutive funding opportunities globally. A wide range of government and private non-dilutive funding sources are available for the disorders being addressed by NeuroPharm. FreeMind Group has the expertise to identify these funding sources and to assist NeuroPharm throughout the funding process, from the preparation and submission of funding applications to pre-award negotiations

6. *Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.*

There were no contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced, expired or terminated during the month of October 2020.

7. *Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.*

There were no acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the month of October 2020.

8. *Describe the acquisition of new customers or loss of customers.*

There were no acquisitions of new customers or loss of customers during the month of October 2020.

9. *Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.*

On October 7, 2020, NeuroPharm filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of matter claims regarding a psychedelic therapy enhancer for the treatment of certain psychiatric disorders, including enhancements to treatments for PTSD. The provisional patent application covers, among other things, an enhancer that reduces the enzymatic breakdown of psilocin, the active ingredient in psilocybin that causes psychedelic effects. This may result in an enhanced psychedelic experience in the treatment of PTSD, whether by extended in time, intensity, intensity per dose, or a combination thereof.

10. *Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.*

There were no employee hirings, terminations or lay-offs during the month of October 2020.

11. *Report on any labour disputes and resolutions of those disputes if applicable.*

There were no labour disputes during the month of October 2020.

12. *Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.*

There were no legal proceedings to which the Issuer became a party to during the month of October 2020.

13. *Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.*

On October 14, 2020, the Issuer announced that its board of directors has approved the settlement of a principal amount of \$847,500.00 in debt for services rendered through the issuance of common shares (the "Debt Settlement"). Pursuant to the Debt Settlement, the Issuer issued 3,684,783 common shares of the Issuer (the "Shares") at a deemed price of \$0.23 per Share to a creditor of the Issuer.

14. *Provide details of any securities issued and options or warrants granted.*

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Stock Options	100,000	Pursuant to Stock Option Plan	N/A
Common Shares	3,684,783	In connection with the Debt Settlement	N/A
Convertible Debentures	\$4,700,000	Non-Brokered Private Placement	Capital projects and general working capital

15. *Provide details of any loans to or by Related Persons.*

There were no loans to or by Related Persons during the month of October 2020.

16. *Provide details of any changes in directors, officers or committee members.*

There were no changes in directors, officers or committee members of the Issuer during the month of October 2020.

17. *Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.*

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Management Discussion and Analysis for the period ended June 30, 2020 (the "MD&A") under the headings "Financial Instruments", "Risks" and "Risks and Uncertainties". The MD&A is available on the Issuer's SEDAR profile at www.sedar.com and on the Issuer's disclosure hall with the CSE at www.thecse.com. Additional trends that are likely to impact the Issuer include:

COVID-19

The outbreak of the coronavirus (“COVID-19”) pandemic has impacted the Issuer’s plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer’s personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the Issuer’s operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets may reduce resource prices, share prices and financial liquidity and thereby that may severely limit the financing capital available.

[The balance of this page is left intentionally blank.]

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated November 5, 2020

David Joshua Bartch
Name of Director or Senior Officer

"David Joshua Bartch"
Signature

President and CEO
Official Capacity

<i>Issuer Details</i> Name of Issuer MYDECINE INNOVATIONS GROUP INC.	For Month End October 2020	Date of Report YY/MM/DD 20/11/05
Issuer Address Suite 810 – 789 West Pender Street		
City/Province/Postal Code Vancouver, BC V6C 1H2	Issuer Fax No. N/A	Issuer Telephone No. (604) 687-2038
Contact Name David Joshua Bartch	Contact Position President & CEO	Contact Telephone No.
Contact Email Address jbartch@mydecineinc.com	Web Site Address www.mydecine.com	